Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 6:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 649–672 of 8,260 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Risk Clear all
Recruiting Phase 4 Interventional

Precision Pain Management - A Randomized Clinical Trial Assessing the Efficacy of Suzetrigine on Postoperative Analgesia Among Surgical Patients at Higher Risk for Persistent Postoperative Opioid Use (POU)

NCT07672015
View directory record Official record
Conditions
Opioid Consumption, Postoperative
Interventions
Suzetrigine, Standard Care (in control arm)
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Completed No phase listed Observational

A Study to Assess the Validation and Mapping of the Suicide Ideation and Behavior Assessment

NCT03085108
View directory record Official record
Conditions
Suicidality
Interventions
No Intervention
Other
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
12 Years to 85 Years
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Birmingham, Alabama • Garden Grove, California • Piscataway, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 29, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

A Bilingual Virtually-based Intervention (PEDALL) for the Prevention of Weight Gain in Childhood ALL Patients Considering Key Genetic and Sociodemographic Risk Factors

NCT05963971
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Obesity
Interventions
PEDALL, Standard of care
Behavioral · Other
Lead sponsor
Columbia University
Other
Eligibility
5 Years to 21 Years
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 29, 2026, 6:55 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

The Effect of Human Albumin Infusion on VEGF Levels in Women at Risk for Ovarian Hyperstimulation Syndrome

NCT00617864
View directory record Official record
Conditions
Ovarian Hyperstimulation Syndrome
Interventions
Human Albumin Infusion, Saline Infusion
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 22, 2012 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Metabolomic and Inflammatory Effects of Oral Aspirin (ASA) in Subjects at Risk for Melanoma

NCT04062032
View directory record Official record
Conditions
Melanoma (Skin)
Interventions
Aspirin 81 mg, Aspirin 325mg
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 18, 2022 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Alemtuzumab and Rituximab in Treating Patients With High-Risk, Early-Stage Chronic Lymphocytic Leukemia

NCT00436904
View directory record Official record
Conditions
Leukemia
Interventions
Alemtuzumab, Rituximab
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 1, 2011 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Complete Health Improvement Program (CHIP) Risk Reduction/Claims Evaluation Project

NCT02977884
View directory record Official record
Conditions
Cardiovascular Diseases, Diabetes Mellitus, Hypertension, Dyslipidemias, Overweight and Obesity
Interventions
The Complete Health Improvement Program
Behavioral
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
389 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2023
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Phase 3 Interventional

Casopitant And ZOFRAN To Prevent Post Operative Nausea And Vomiting In Women

NCT00334152
View directory record Official record
Conditions
Nausea and Vomiting, Postoperative, Postoperative Nausea and Vomiting
Interventions
casopitant
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older · Female only
Enrollment
515 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
25
States / cities
Fairhope, Alabama • Mobile, Alabama • Montgomery, Alabama + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2017 · Synced Oct 29, 2026, 6:55 PM EDT
Not listed Phase 2Phase 3 Interventional

A Multi-Center Study on the Use of Rho-Kinase Inhibitor to Reduce or Prevent PVR in RRD Eyes at High Risk for PVR

NCT05660447
View directory record Official record
Conditions
Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
Interventions
Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 29, 2026, 6:55 PM EDT
Recruiting Not applicable Interventional

Preventing Suicidal Behavior With Diverse High-Risk Youth in Acute Care Settings

NCT06151158
View directory record Official record
Conditions
Suicide, Attempted, Suicide Ideation, Suicide, Suicide Prevention
Interventions
Stanley Brown Safety Planning Intervention and Follow-up Contacts (SPI+), Interpersonal Psychotherapy for Adolescents Ultra Short Crisis Intervention (IPT-A SCI)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 24 Years
Enrollment
484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
6
States / cities
St. Petersburg, Florida • Baltimore, Maryland • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Obesity, Iron Regulation and Colorectal Cancer Risk

NCT03548948
View directory record Official record
Conditions
Colon Inflammation, Iron Malabsorption, Obesity, Diet Modification
Interventions
High heme iron diet, Low iron diet, Plant-based high non-heme iron diet
Other
Lead sponsor
University of Illinois Chicago
Other
Eligibility
55 Years to 70 Years · Female only
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Deprescribing of Diabetes Regimens in Long Term Care Residents With Alzheimer's

NCT05535478
View directory record Official record
Conditions
Diabetes, Dementia, Hypoglycemia; Drug
Interventions
STRIDE
Behavioral
Lead sponsor
Joslin Diabetes Center
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 30, 2025 · Synced Oct 29, 2026, 6:55 PM EDT
Recruiting Phase 2 Interventional

Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)

NCT06797635
View directory record Official record
Conditions
Breast Neoplasms, Breast Cancer
Interventions
Patritumab deruxtecan, Pembrolizumab, Paclitaxel, Carboplatin, Doxorubicin hydrochloride, Epirubicin hydrochloride, Cyclophosphamide, Capecitabine, Olaparib
Biological · Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
372 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2034
U.S. locations
8
States / cities
Santa Monica, California • Skokie, Illinois • Billings, Montana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Recruiting Phase 2Phase 3 Interventional Accepts healthy volunteers

Naltrexone for Overdose Prevention

NCT06633900
View directory record Official record
Conditions
Overdose Accidental
Interventions
IM naltrexone, Usual Care
Drug · Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Gallium-68 PSMA-11 PET in Intermediate to High-risk Preprostatectomy Patients

NCT02919111
View directory record Official record
Conditions
Prostate Cancer
Interventions
Ga-68 labeled PSMA-11 PET
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Oct 29, 2026, 6:55 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Web-Based Family Outreach Program for Cancer Prevention in High-Risk Families

NCT02337452
View directory record Official record
Conditions
Malignant Neoplasm
Interventions
Questionnaire Administration, Web Site
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2048
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Active, not recruiting No phase listed Observational

A Multi Modality Surveillance Program for Women At High Risk for Breast Cancer

NCT00989638
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
305 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Not applicable Interventional

Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma

NCT03612648
View directory record Official record
Conditions
Breast Carcinoma, Breast Cancer
Interventions
Three Fraction Accelerated Partial Breast Irradiation, Partial mastectomy
Radiation · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
50 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Phase 2 Interventional Results available

Comparison of SYN023 to Human Rabies Immune Globulin in Post Exposure Prophylaxis of Rabies

NCT03961555
View directory record Official record
Conditions
Rabies
Interventions
SYN023, HRIG (HyperRab), Rabies vaccine
Biological
Lead sponsor
Synermore Biologics Co., Ltd.
Industry
Eligibility
18 Years and older
Enrollment
448 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
5
States / cities
Gainesville, Florida • Iowa City, Iowa • Milan, Tennessee + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Terminated Not applicable Interventional Results available

Rapid Assessment of Esophageal Adenocarcinoma Risk Test

NCT03366012
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Adenocarcinoma
Interventions
Cytosponge
Device
Lead sponsor
Columbia University
Other
Eligibility
50 Years to 75 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Osteoporosis Choice Decision Aid for Use of Bisphosphonates in Postmenopausal Women

NCT00578981
View directory record Official record
Conditions
Osteoporosis, Bone Loss, Age Related, Postmenopausal Bone Loss, Postmenopausal Osteoporosis
Interventions
Osteoporosis Choice Decision Aid
Behavioral
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 90 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 2, 2016 · Synced Oct 29, 2026, 6:55 PM EDT
Completed Not applicable Interventional Results available

Family-focused vs. Drinker-focused Smartphone Interventions to Reduce Drinking-related Consequences of COVID-19

NCT05419128
View directory record Official record
Conditions
Alcohol Use Disorder, Family Members, Behavior, Addictive
Interventions
PartnerCHESS, ACHESS
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
398 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Stress Reactivity and Mother-Infant Cardiovascular Disease Risk

NCT06805799
View directory record Official record
Conditions
Maternal Health, Infant Health, Hypertension, Behavioral Medicine, Mindfulness, Psychophysiology, Cardiovascular Diseases, Cardiovascular Diseases Risk
Interventions
Follow up to Mindfulness RCT using a Still Face Paradigm
Other
Lead sponsor
Lifespan
Other
Eligibility
6 Months and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Oct 29, 2026, 6:55 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

NCT01469221
View directory record Official record
Conditions
Bladder Cancer
Interventions
Apaziquone, Placebo
Drug
Lead sponsor
Spectrum Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
7
States / cities
Los Angeles, California • Miami, Florida • Somerville, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2017 · Synced Oct 29, 2026, 6:55 PM EDT